KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Q3 2025 value amounting to -$27.2 million.

  • Acadia Pharmaceuticals' Tax Provisions fell 55025.66% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 5124.94%. This contributed to the annual value of $31.6 million for FY2024, which is 20702.91% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Tax Provisions is -$27.2 million, which was down 55025.66% from $13.5 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Tax Provisions high stood at $17.3 million for Q4 2024, and its period low was -$27.2 million during Q3 2025.
  • Its 5-year average for Tax Provisions is $2.1 million, with a median of $800000.0 in 2022.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Tax Provisions skyrocketed by 228095.24% in 2022 and then tumbled by 82731.65% in 2023.
  • Acadia Pharmaceuticals' Tax Provisions (Quarter) stood at $189000.0 in 2021, then surged by 339.68% to $831000.0 in 2022, then plummeted by 827.32% to -$6.0 million in 2023, then soared by 386.63% to $17.3 million in 2024, then crashed by 257.01% to -$27.2 million in 2025.
  • Its last three reported values are -$27.2 million in Q3 2025, $13.5 million for Q2 2025, and $8.8 million during Q1 2025.